EP1490089A4 - SELECTIVE LETALE PEPTIDES FOR MALIGN AND TRANSFORMED MAMMALIAN CELLS - Google Patents

SELECTIVE LETALE PEPTIDES FOR MALIGN AND TRANSFORMED MAMMALIAN CELLS

Info

Publication number: EP1490089A4
Authority: EP; European Patent Office
Prior art keywords: letale; malign; peptides; selective; mammalian cells
Prior art date: 2002-03-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP03760194A

Other languages

German (de)

French (fr)

Other versions

EP1490089A1 (en

Inventor

Matthew R Pincus

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Research Foundation of the State University of New York

Original Assignee

Research Foundation of the State University of New York

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-12

Filing date

2003-03-12

Publication date

2006-08-30

2003-03-12 Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York

2004-12-29 Publication of EP1490089A1 publication Critical patent/EP1490089A1/en

2006-08-30 Publication of EP1490089A4 publication Critical patent/EP1490089A4/en

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Immunology (AREA)
Toxicology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Marine Sciences & Fisheries (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

EP03760194A 2002-03-12 2003-03-12 SELECTIVE LETALE PEPTIDES FOR MALIGN AND TRANSFORMED MAMMALIAN CELLS Withdrawn EP1490089A4 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US36378502P	2002-03-12	2002-03-12
US363785P		2002-03-12
PCT/US2003/007687 WO2003105880A1 (en)	2002-03-12	2003-03-12	Peptides selectively lethal to malignant and transformed mammalian cells

Publications (2)

Publication Number	Publication Date
EP1490089A1 EP1490089A1 (en)	2004-12-29
EP1490089A4 true EP1490089A4 (en)	2006-08-30

Family

ID=29736031

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP03760194A Withdrawn EP1490089A4 (en)	2002-03-12	2003-03-12	SELECTIVE LETALE PEPTIDES FOR MALIGN AND TRANSFORMED MAMMALIAN CELLS

Country Status (5)

Country	Link
EP (1)	EP1490089A4 (en)
JP (1)	JP2005520866A (en)
AU (1)	AU2003277292A1 (en)
CA (1)	CA2477878C (en)
WO (1)	WO2003105880A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040038902A1 (en) *	2000-04-05	2004-02-26	Pincus Matthew R.	Peptides selectively lethal to malignant and transformed mammalian cells
EP1706419A2 (en) *	2004-01-13	2006-10-04	The Research Foundation of the State University of New York	Modified fusion peptides derived from a p53 domain against malignant and/or transformed mammalian cells
WO2005074521A2 (en) *	2004-01-30	2005-08-18	The Trustees Of Columbia University In The City Of New York	C-TERMINAL p53 PALINDROMIC PEPTIDE THAT INDUCES APOPTOSIS OF CELLS WITH ABERRANT p53 AND USES THEREOF
WO2008081812A1 (en) *	2006-12-28	2008-07-10	Toagosei Co., Ltd.	Anti-tumor peptide and use thereof
EP2224961A1 (en)	2007-11-26	2010-09-08	The Research Foundation of the State University of New York	Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
US8822419B2 (en)	2008-10-03	2014-09-02	The Research Foundation Of State University Of New York	Membrane resident peptide in anti-cancer peptides causes tumor cell necrosis rather than apoptosis of cancer cells
WO2011005219A1 (en) *	2009-07-07	2011-01-13	Agency For Science, Technology And Research	Novel mdm2 binding peptides and uses thereof
AU2019247554A1 (en)	2018-04-06	2020-11-26	Oncolyze, Inc.	Compositions for use in lysis of selective cancer cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996002642A1 (en) *	1994-07-20	1996-02-01	University Of Dundee	INTERRUPTION OF BINDING OF MDM2 AND p53 PROTEIN AND THERAPEUTIC APPLICATION THEREOF
WO2004081030A2 (en) *	2003-03-12	2004-09-23	The Research Foundation Of The State University Of New York	Peptides selectively lethal to malignant and transformed mammalian cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4215102A (en) *	1979-01-05	1980-07-29	Lee Sin H	Cytochemical agents and methods for the detection of steroid hormone receptors in human tissues
US5369012A (en) *	1992-03-26	1994-11-29	The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration	Method of making a membrane having hydrophilic and hydrophobic surfaces for adhering cells or antibodies by using atomic oxygen or hydroxyl radicals

2003
- 2003-03-12 JP JP2004512781A patent/JP2005520866A/en active Pending
- 2003-03-12 EP EP03760194A patent/EP1490089A4/en not_active Withdrawn
- 2003-03-12 WO PCT/US2003/007687 patent/WO2003105880A1/en not_active Ceased
- 2003-03-12 CA CA2477878A patent/CA2477878C/en not_active Expired - Lifetime
- 2003-03-12 AU AU2003277292A patent/AU2003277292A1/en not_active Abandoned

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996002642A1 (en) *	1994-07-20	1996-02-01	University Of Dundee	INTERRUPTION OF BINDING OF MDM2 AND p53 PROTEIN AND THERAPEUTIC APPLICATION THEREOF
WO2004081030A2 (en) *	2003-03-12	2004-09-23	The Research Foundation Of The State University Of New York	Peptides selectively lethal to malignant and transformed mammalian cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KANOVSKY MECHEAL ET AL: "Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 98, no. 22, 23 October 2001 (2001-10-23), pages 12438 - 12443, XP002391084, ISSN: 0027-8424 *
See also references of WO03105880A1 *

Also Published As

Publication number	Publication date
CA2477878C (en)	2013-05-14
AU2003277292A1 (en)	2003-12-31
WO2003105880A1 (en)	2003-12-24
JP2005520866A (en)	2005-07-14
CA2477878A1 (en)	2003-12-24
EP1490089A1 (en)	2004-12-29

Publication	Publication Date	Title
EP1495128A4 (en)	2006-11-02	REINFORCED PROTEIN EXPRESSION IN BACILLUS
DK1680443T3 (en)	2013-12-16	Stabilized alpha-helix peptides and uses thereof
EP1732581A4 (en)	2008-06-04	POLYPEPTIDE TRANSDUCTION AND FUSOGENIC PEPTIDES
DE60330151D1 (en)	2009-12-31	FUEL CELL SYSTEM
DE60217210D1 (en)	2007-02-15	Rechargeable lithium cell and connection structure for it
DE60316596D1 (en)	2007-11-08	FUEL CELL SYSTEM
DE60329983D1 (en)	2009-12-24	WAXESESYNTHASE DNA SEQUENCE, PROTEIN AND USES THEREOF
NO20044141D0 (en)	2004-09-29	Electrochemical fuel cells
DE60306039D1 (en)	2006-07-27	Memory cell and memory device
IS7499A (en)	2004-10-11	Human antibodies against beta-amyloid peptides
DE60334419D1 (en)	2010-11-18	Photovoltaic cell
DE60331474D1 (en)	2010-04-08	FUEL CELL SYSTEM
DE60308922D1 (en)	2006-11-23	Gas-tight prismatic battery
DE60313442D1 (en)	2007-06-06	ELECTROLYTE FILM AND FESTPOLYMER FUEL CELL THEREWITH
DE60329081D1 (en)	2009-10-15	Hybrid fuel cell system and associated control method
DE60331959D1 (en)	2010-05-12	FUEL CELL SYSTEM
DE60303684D1 (en)	2006-04-27	FUEL CELL SYSTEM AND RELATED CONTROL METHOD
DE60209150D1 (en)	2006-04-20	SEALING SYSTEM FOR ELECTROLYSIS CELL
DE60313835D1 (en)	2007-06-28	Fuel cell system and corresponding operating method
EP1608409A4 (en)	2009-09-16	SELECTIVE LETALE PEPTIDES FOR MALIGN AND TRANSFORMED MAMMALIAN CELLS
EP1490089A4 (en)	2006-08-30	SELECTIVE LETALE PEPTIDES FOR MALIGN AND TRANSFORMED MAMMALIAN CELLS
DE60307959D1 (en)	2006-10-12	Exhaust treatment device for fuel cell
EP1673790A4 (en)	2011-09-28	COMBINED PHOTOELECTROMECHANICAL CELL AND CONDENSER
DE60312367D1 (en)	2007-04-19	FUEL CELL SYSTEM
DE60324930D1 (en)	2009-01-08	ELECTROLYTE FOR FUEL CELL

Legal Events

Date	Code	Title	Description
2004-11-12	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2004-12-29	17P	Request for examination filed	Effective date: 20041004
2004-12-29	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
2004-12-29	AX	Request for extension of the european patent	Extension state: AL LT LV MK
2006-08-30	A4	Supplementary search report drawn up and despatched	Effective date: 20060801
2006-11-02	17Q	First examination report despatched	Effective date: 20061005
2007-09-07	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2007-10-10	18D	Application deemed to be withdrawn	Effective date: 20070417